Table 2.
Androgenic activity 11-oxysteroid derivatives of testosterone and androstenedione
| Steroid | Adult female average serum levela ng/dL | Adult female average serum levela nmol/L | EC50b nmol/L | Potency relative to testosteroneb (%) | Maximal fold-induction luciferase (at concentration) |
|---|---|---|---|---|---|
| Testosterone | 32 | 1.1 | 0.52 | 100 | 16 (at 10 nmol/L) |
| 11KT | 21 | 0.7 | 2.7 | 33 (101) | 16 (at 30 nmol/L) |
| 11OHT | 11 | 0.4 | 2.3 | 22 (30) | 12 (at 30 nmol/L) |
| Androstenedione | 89 | 3.1 | 87 | 4.0 | 8 (at 1000 nmol/L) |
| 11KA | 15 | 0.5 | 469 | 0.3 | 10 (at 1000 nmol/L) |
| 11OHA | 117 | 3.9 | - | <0.3 | 1 (at 1000 nmol/L) |
Data from Rege et al (15).
Abbreviation: EC50, half maximal effective concentration
a From Davio et al (99).
b Relative potency determined from the concentration of a steroid that exerts the same effect as an EC50 concentration of testosterone. Extrapolated from data in Figure 1 of Rege et al (15). Potency data in parentheses indicates estimates of relative agonist activity obtained at 1.0 nM by Storbeck et al (63).